drugset
drugset / Trial / NCT04540874

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

NCT04540874 ↗

Phase 1 Terminated 8 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The objective of this trial is to investigate the safety, tolerability and pharmacokinetics of BI 894416 in healthy Japanese male subjects.

Timeline

Start
2020-10-05
Primary completion
2020-11-12
Completion
2020-11-12

Outcome

Outcome not reported

Stopped: “due to company decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 894416 Unknown 25 mg Oral

Indications

No indication recorded.